Matthew F. Krummel (Max Krummel) is a Professor in the Pathology Department at University of California, San Francisco. He is known for Systems Immunology and studies mechanisms that regulate the immune system.
Matthew F. Krummel | |
|---|---|
| Born | Matthew Frederick Krummel May 28, 1968 |
| Education | University of Illinois at Urbana-Champaign College of Liberal Arts & Sciences (B.S.) University of California, Berkeley, (PhD) Stanford University, (Postdoctorate) |
| Known for | Systems Immunology |
| Scientific career | |
| Fields | Immunology, Pathology |
| Institutions | University of California, San Francisco |
| Thesis | Identification and Characterization of a CTLA-4 Dependent Regulatory Mechanism for T Cell Activation. (1995) |
| Doctoral advisor | James P. Allison |
Career
editKrummel holds the Robert E. Smith Endowed Chair in Pathology[1] and is the Chair of the UCSF ImmunoX Initiative.[2][3] His lab (krummellab)[4] uses real-time imaging to launch and test hypotheses related to how the immune system processes information and makes decisions.[5] His recent discoveries include determining features of T cell membrane biology and how the movement of immune cells governs their ability to efficiently survey for antigens. Additionally, his research has revealed archetypal collections of immune systems in cancer, namely those involving networks of cells built around stimulatory dendritic cells.[6][1][7]
Krummel developed a novel industry consortium-funded project (immunoprofiler.org) that unites studies of cancer indications to understand the biology of individual patients and founded a microscopy ‘collaboratory’ at UCSF.[8][9][10] He also founded the ImmunoX initiative, together with other UCSF faculty, which is a radical collaboration platform focused on methods and data sharing as a means to accelerate discovery and cures.[2][3]
Krummel co-founded Foundery Innovations, a novel biotechnology venture fund and studio that translates early-stage drug concepts through extensive academic-industry collaborations, most recently with the University of California, San Francisco, and the University of Arizona.[11][12][13] He founded Pionyr Immunotherapeutics where he discovered new next-generation immunotherapeutics targeting myeloid cells.[14][12] In the lab of James P. Allison at UC Berkeley, Krummel conducted key studies on the function of the protein CTLA-4; together they developed and described the first CTLA-4 inhibitors. They subsequently collaborated to apply the same inhibitors in tumor models, providing data on the blockade of inhibitory receptors can augment tumor immune responses, the basis for the 2018 Nobel Prize in Medicine and Physiology as well as the first patents for anti-CTLA-4 checkpoint blockade.[15][16][7]
Krummel received his Ph.D. at the University of California, Berkeley, and completed his postdoctoral studies at Stanford University.[1]
Honors
edit- 2020 Dial Fellow, Emerson Collective.[17]
- 2009 Fellow of the American Asthma Foundation.[18]
- 2005 Leukemia and Lymphoma Foundation, Career Award.[18]
- 2004 Cancer Research Institute, Investigator Award.[19]
Positions and employment
editThis biographical section is written like a résumé. (July 2023) |
- 2021 – Present Co-Founder and Managing Member, Foundery Innovations.
- 2015 – May 2021 Founder and Founding Chief Executive Officer, Pionyr Immunotherapeutics.
- 2018 – Present Co-Founder and Inaugural Chair, ImmunoX Initiative, University of California at San Francisco.[2]
- 2012 – Present Professor, Department of Pathology, University of California at San Francisco.[1]
- 2006 – Present Faculty Director, Biological Imaging Development Center, University of California at San Francisco
Selected publications
edit- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995 Aug 01; 182(2):459-65. Krummel MF, Allison JP. PMID 7543139; PMCID: PMC2192127.
- Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996 Mar 22; 271(5256):1734-6. Leach DR, Krummel MF, Allison JP. PMID 8596936.
- Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018 05; 24(5):541–550. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. PMID 29686425; PMCID: PMC5998822.
- Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10; 26(5):638-52. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. PMID 25446897; PMCID: PMC4254577.
- A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018 08; 24(8):1178–1191. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. PMID 29942093; PMCID: PMC6475503.
References
edit- ^ a b c d "Max Krummel, PhD". UCSF Helen Diller Family Comprehensive Cancer Center. Retrieved 26 June 2023.
- ^ a b c "'ImmunoX' Initiative a Radical Collaboration Across UCSF | UC San Francisco". www.ucsf.edu. Retrieved 26 June 2023.
- ^ a b "UCSF's ImmunoX revolution, Gilead's deal, a pain breakthrough and more". www.bizjournals.com. Retrieved 26 June 2023.
- ^ "Home". krummellab.com. Retrieved 26 June 2023.
- ^ "Matthew Krummel". Allen Institute. Retrieved 26 June 2023.
- ^ Keystone Symposia on Molecular and Cellular Biology [Abstracts, 23rd annual meeting], February 26 – April 17, 1994. Wiley-Liss. 1994. OCLC 1355108639.
- ^ a b "Present at Creation of Nobel-Winning 'Checkpoint Inhibitor' Therapies, Immunologist Looks to the Future". www.ucsf.edu. Retrieved 26 June 2023.
- ^ "UCSF Department of Medicine 2018–2019 Biennial Report: Transforming Medicine Through Collaboration". issuu.com. Retrieved 26 June 2023.
- ^ "'Immune Archetypes' Of Cancer Could Help Tailor Treatments To Tumors". Pubs – Bio-IT World. Retrieved 26 June 2023.
- ^ "Team". UCSF Immunoprofiler. Retrieved 26 June 2023.
- ^ "The University of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies". www.kake.com.
- ^ a b "UCSF signs deal with 'bridging' venture to spin out academic innovation". www.bizjournals.com. Retrieved 26 June 2023.
- ^ "Foundery Innovations Establishes Scientific Advisory Board with Appointment of Key Opinion Leaders in Immunology and Oncology". Bloomberg.com. 2023-03-28. Retrieved 26 June 2023.
- ^ "Why this startup is playing in one of the hottest areas of cancer". www.bizjournals.com.
- ^ "UC Berkeley Cancer Research Lab » The Story of Yervoy (Ipilimumab)". crl.berkeley.edu. Retrieved 26 June 2023.
- ^ "Present at Creation of Nobel-Winning 'Checkpoint Inhibitor' Therapies, Immunologist Looks to the Future". www.ucsf.edu. Retrieved 27 June 2023.
- ^ "Who do we follow when we "follow the science"? – Emerson Collective". www.emersoncollective.com. Retrieved 27 June 2023.
- ^ a b "Matthew Krummel, PhDMatthew Krummel, PhD". UCSF Pathology. Retrieved 27 June 2023.
- ^ PhD, Arthur N. Brodsky (31 October 2019). "PORTER Immunotherapy Clinical Trial Unveiled". Cancer Research Institute. Retrieved 3 July 2023.